Burning Rock Schedules Second Quarter of 2020 Earnings Release on August 11, 2020
Burning Rock Biotech Limited (NASDAQ: BNR) plans to announce its second quarter 2020 financial results on August 11, 2020, before the U.S. market opens. Following this, a conference call will take place at 8:00 a.m. ET to discuss the results. The company specializes in next-generation sequencing (NGS) technology for precision oncology, with a significant market presence in China, having completed over 185,000 tests. Burning Rock is committed to innovative NGS testing products and has received key certifications in laboratory quality systems.
- Leading market share in China for NGS-based therapy selection testing.
- Over 185,000 tissue and liquid-based tests completed.
- Development of NGS-based cancer early detection advancing to clinical validation.
- Received first approval for a tumor NGS kit in July 2018 from NMPA.
- None.
GUANGZHOU, China, July 20, 2020 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR) today announced that it plans to release its unaudited financial results for the second quarter of 2020 before the U.S. market opens on August 11, 2020. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) the same day to discuss financial results.
Details of the conference call are as follows:
| 20%; width: | 80%; width: |
| U.S.: | 18665194004 |
| U.K.: | 08082346646 |
| Hong Kong: | +852 30186771 |
| China Mobile: | 4006208038 |
| China Landline: | 8008190121 |
| Conference ID: | 4765946 |
A replay of the second quarter 2020 conference call will be available for two weeks (dial-in number: +61 2 8199 0299; same conference ID as shown above).
Please visit the company’s investor relations website at https://ir.brbiotech.com/news-events/news-releases on August 11, 2020 to view the earnings release prior to the conference call.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to Guard Life via Science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 185,000 tissue and liquid-based tests completed cumulatively, and ii) NGS-based cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage. In July 2018, Burning Rock received the first approval for a tumor NGS kit by the National Medical Products Administration (NMPA), which is a significant milestone in the field of in vitro diagnosis in China. Burning Rock’s laboratory has obtained the technical certification of “High-throughput sequencing laboratory” issued by Guangdong Center for Clinical Laboratory, and the CLIA and CAP laboratory quality system certification. The company continues to be committed to the development of innovative and reliable NGS testing products and promoting the development of precision medicine in oncology.
For more information about Burning Rock, please visit: www.brbiotech.com.
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
FAQ
When will Burning Rock Biotech release its Q2 2020 financial results?
What time is the conference call for Burning Rock's Q2 2020 results?
What is the stock symbol for Burning Rock Biotech?
What does Burning Rock Biotech specialize in?
How many tests has Burning Rock Biotech completed?
